Skip to main
ABVX

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 31%
Buy 62%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Abivax is a clinical-stage biotechnology company developing innovative therapeutics to treat chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms. Through its lead candidate, obefazimod, the company is targeting ulcerative colitis and Crohn's disease. With a strong efficacy and safety profile, backed by positive clinical trials and expert support, Abivax is poised for success in the $30 billion IBD market. The recent positive Part 2 maintenance readout, increased UC revenue estimates, and strengthened balance sheet through an equity financing contribute to our bullish outlook on the stock.

Bears say

Abivax is facing intense pressure in the biotech industry as it races to bring its drug candidate, obefazimod, to the market for the treatment of inflammatory bowel diseases. Despite positive feedback from key opinion leaders, concerns about the company's financial situation and the upcoming catalysts have led to a negative outlook from financial analysts. With only one operating segment focused on R&D, Abivax may struggle to generate sufficient financial resources to support its pipeline, making it a high-risk investment.

Abivax SA (ABVX) has been analyzed by 13 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 62% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 13 analysts, Abivax SA (ABVX) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $148.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $148.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.